Antibody Drug Conjugates

Antibody Drug Conjugates (ADCs) represent a pioneering class of targeted cancer therapies that hold tremendous promise in revolutionizing the landscape of cancer treatment. At the heart of ADCs lies a sophisticated combination of monoclonal antibodies, potent cytotoxic drugs, and linker molecules, meticulously engineered to precisely target and eliminate cancer cells while minimizing damage to healthy tissues.

These cutting-edge biopharmaceuticals function through a multi-step mechanism. First, the monoclonal antibody component of the ADC selectively binds to antigens overexpressed on the surface of cancer cells, ensuring precise localization. This targeted approach significantly enhances the therapeutic index, as it spares normal cells from toxic effects.

Following antigen binding, the ADC undergoes internalization into the cancer cell via endocytosis. Within the intracellular compartments, the ADC encounters the acidic environment of lysosomes, triggering the cleavage of the linker molecule that connects the antibody and the cytotoxic payload.

Once liberated, the cytotoxic drug payload is released into the cytoplasm of the cancer cell, where it exerts its potent cytotoxic effects. These drugs, often potent chemotherapeutic agents or toxins, disrupt essential cellular processes such as DNA replication or protein synthesis, leading to cancer cell death.